Dexcom's Next Generation G7 Diabetes Sensor Receives CE Mark in Europe
Shots:
- Dexcom G7 CGM system has received a CE mark for people with diabetes aged ≥2yrs., including pregnant women in the EU
- The G7 offers a short warm-up period, sending real-time blood sugar readings and alerts 30min after being applied without the need for calibrating fingersticks. The device provides 12hrs. grace period to replace finished sensors for a more seamless transition between sessions
- Dexcom is closely working with insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems. The company is planning to launch Dexcom G7 in Europe in the coming weeks
Ref: Businesswire India | Image: Businesswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
